Printer Friendly

AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS

 LA JOLLA, Calif., Oct. 29 /PRNewswire/ -- Agouron Pharmaceuticals Inc. (NASDAQ-NMS: AGPH) today announced a net loss of $3,273,000, or $.45 per common share, on revenues of $3,384,000 for the quarter ended Sept. 30, 1993. The net loss recorded in the comparable period of the prior fiscal year was $2,476,000, or $.36 per common share, on revenues of $2,243,000. Operating results for the first three months of the fiscal year reflect Agouron's continuing investment in proprietary research and development activities.
 Agouron Pharmaceuticals Inc. is a pioneer and leader in a technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases.
 AGOURON PHARMACEUTICALS INC.
 Summary Financial Information
 (In thousands, except per share amounts)
 Three Months Ended
 Sept. 30,
 1993 1992
 Statement of Operations Data
 (Unaudited):
 Total revenues $3,384 $2,243
 R&D spending $6,054 $4,217
 Net loss ($3,273) ($2,476)
 Net loss per share ($.45) ($.36)
 Wt. Avg. No. Shares 7,227 6,906
 Sept. 30, June 30,
 Balance Sheet Data: 1993 1993
 (Unaudited)
 Current Assets $33,578 $35,284
 Total assets $40,025 $41,721
 -0- 10/29/93
 /CONTACT: Steven S. Cowell, VP & CFO, or Donna Nichols, Director- Corporate Communications, Agouron Pharmaceuticals, 619-622-3009/
 (AGPH)


CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: ERN

JL-MF -- SD001 -- 8331 10/29/93 08:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 29, 1993
Words:260
Previous Article:MOUNTAINEER BANKSHARES OF W.VA., INC. ANNOUNCES FOURTH QUARTER DIVIDEND
Next Article:PROCYTE CORP. REPORTS THIRD QUARTER FINANCIALS; CLINICAL PROGRAMS PROGRESSING ON SCHEDULE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters